Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.38 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417355 | 0.79 | GSK3B (0.59) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| Hydrochloric Acid SCHEMBL4425167 | 0.78 | GSK3B (0.59) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL23780643 | 0.77 | GSK3B (0.60) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| Hydrochloric Acid SCHEMBL18813497 | 0.77 | GSK3B (0.59) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL3603972 | 0.75 | EGLN2 (0.32) | PIK3CAPIK3CBPIK3CG | |
| SCHEMBL4675036 | 0.74 | GSK3B (0.51) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL5076249 | 0.74 | GSK3B (0.62) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4669937 | 0.74 | GSK3B (0.50) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL14175422 | 0.74 | GSK3B (0.64) | GSK3BGSK3ACDK1CCNB2CCNB1 | |
| SCHEMBL4675353 | 0.73 | GSK3B (0.50) | GSK3BGSK3ACDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135534-A1 | Pyrazine based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CDK1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.